Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

Inclusion Criteria: * Histologically confirmed metastatic or unresectable malignancy for which standard curative or palliative therapy does not exist or is no longer effective * Progressive disease manifested by the following parameters * For prostate cancer: * Must have castrate, metastatic disease defined by disease progression after surgical castration or treatment with a gonadotropin-releasing hormone (GnRH) analog (testosterone level less than 50 ng/mL) * Patients who have not undergone surgical orchiectomy should continue on medical therapies to maintain castrate levels of testosterone * Progressive metastatic disease on imaging studies (bone scan, CT scan, or MRI) OR metastatic disease and a rising prostate-specific antigen (PSA) * Biochemical progression indicated by at least 3 rising PSA values (obtained at least 1 week apart) from a baseline OR 2 rising PSA values (more than 1 month apart), where the percentage increase over the range of values is at least 25% * Patients who have received an antiandrogen as part of first-line hormonal therapy must have shown progression of disease off of the antiandrogen prior to study enrollment * For other solid tumors: * Development of new lesions or an increase in pre-existing lesions by bone scintigraphy, CT scan, MRI, positron emission tomography, or physical examination * Patients whose sole criterion for progression is an increase in a biochemical marker (e.g., carcinoembryonic antigen …